Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.
First UK baby born from deceased donor womb transplant
A baby boy has become the first child in the UK to be born following a womb transplant from a deceased donor, marking what doctors called a “ground-breaking moment” for reproductive medicine. Hugo was born just before Christmas 2025 at Queen Charlotte's and Chelsea Hospital to Grace Bell, who was born without a viable womb due to Mayer Rokitansky Küster Hauser (MRKH) syndrome, a condition affecting roughly one in 5,000 women. The birth is the first in the UK to result from a deceased-donor womb transplant under a clinical trial led by teams in Oxford and London, following decades of research by consultant surgeons Richard Smith and Isabel Quiroga, supported by Womb Transplant UK. Their work includes two programs: a living donor initiative aiming for five transplants and the UK INvestigational Study into Transplantation of the Uterus, which involves deceased donors and multiple National Health Services collaborators. Surgeons said the milestone offers new hope to women born without a womb, while Bell and her partner paid tribute to the donor’s family for what they described as the “incredible gift” that made their son’s birth possible. – Bree Foster
Early cancer blood test falls short in major UK trial
A highly anticipated UK trial of Grail’s Galleri liquid biopsy test, designed to detect multiple cancers from circulating tumor DNA in blood, failed to show a statistically significant reduction in late-stage (stage 3 or 4) cancer diagnoses compared to controls — missing its primary goal of a 20 percent drop in advanced cancers. The 142,000-patient prospective study was meant to provide the rigorous evidence the field has needed, especially as Galleri has been marketed under CLIA provisions without FDA approval and largely paid for out of pocket. While the concept of multi-cancer early detection via blood is scientifically appealing, the results underscore persistent technical and clinical challenges — including signal detection limits, false positives, and, most importantly, whether earlier detection actually improves outcomes. The disappointing readout now raises pressure on other early-detection companies to produce similarly robust trial data and reinforces a longstanding lesson in medicine: plausible, high-tech ideas still have to prove they reduce morbidity and mortality. – Andrea Corona
GSK commits up to $1 billion for Frontier Biotech siRNA programs
Frontier Biotechnologies has struck an exclusive global licensing deal with GSK covering two small interfering RNA (siRNA) programs, one at the investigational new drug stage and the other preclinical. Under the agreement, Frontier will receive $40 million upfront and is eligible for up to $963 million in development, regulatory, and commercial milestones across the two assets, plus tiered royalties on worldwide sales. Frontier will advance the programs through early development — taking one candidate into a Phase 1 trial in China and completing Investigational New Drug-enabling work for the other — while GSK assumes responsibility for later-stage global development, regulatory filings and commercialization. The deal bolsters GSK’s immunology pipeline with potential first-in-class oligonucleotide therapies, while underscoring growing pharma interest in siRNA platforms as they expand from rare diseases into broader chronic indications. – Bree Foster
Experimental antibody-drug conjugate shows survival benefit in late-stage breast cancer trial
SystImmune and Bristol Myers Squibb reported that izalontamab brengitecan (iza-bren), an EGFR×HER3 bispecific antibody-drug conjugate (ADC), met both progression-free survival (PFS) and overall survival (OS) endpoints in a pre-specified interim analysis of the Phase 3 BL-B01D1-307 trial in China, enrolling patients with previously treated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). In the randomized study, iza-bren demonstrated statistically significant and clinically meaningful improvements compared to physician’s choice chemotherapy, marking the third Phase 3 trial in which the agent has achieved its primary endpoint(s) and a Phase 3 trial for TNBC to report dual positive PFS/OS results. The trial was sponsored by Sichuan Biokin Pharmaceutical, SystImmune’s parent company, with global development outside China conducted in collaboration with Bristol Myers Squibb. Detailed data are expected at an upcoming medical meeting, while the agent has also received Breakthrough Therapy designation in multiple indications in China and for EGFR-mutant non-small cell lung cancer in the United States. — Andrea Corona
Merck restructures human health division to sharpen commercial focus
Merck announced a reorganization of its Human Health business, creating two units — Oncology and Specialty, Pharma and Infectious Diseases — aimed at strengthening commercial execution across a broad and growing portfolio. The move comes as the company advances roughly 80 Phase 3 studies and anticipates more than 20 potential growth drivers in the coming years. Jannie Oosthuizen will lead the Oncology unit, while Brian Foard joins from Sanofi to head the Specialty, Pharma and Infectious Diseases division, both reporting directly to CEO Robert Davis. The company also appointed Chirfi Guindo to oversee a newly integrated Strategic Access, Policy and Communications function, consolidating access, policy and sustainability efforts. The restructuring is designed to align leadership and commercialization strategy as Merck prepares for multiple anticipated product launches across diverse therapeutic areas. — Andrea Corona
Gilead moves to acquire Arcellx, consolidating control of CAR-T candidate
Gilead Sciences announced a $7.8 billion deal to acquire Arcellx, securing full ownership of anitocabtagene autoleucel (anito-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy under FDA review for relapsed or refractory multiple myeloma. The transaction builds on a 2022 co-development partnership between Kite, a Gilead company, and Arcellx, and eliminates future profit-sharing, milestone payments and royalties tied to the program. The biologics license application for anito-cel, supported by Phase 1 and pivotal Phase 2 data, has been accepted by the FDA with a regulatory action date of December 23, 2026. Beyond the potential near-term launch, the acquisition gives Gilead access to Arcellx’s D-Domain CAR technology platform, which could support next-generation cell therapies. The tender offer values Arcellx at $115 per share in cash plus a contingent value right tied to future sales milestones, with closing expected in the second quarter of 2026 pending regulatory and shareholder approvals. - Andrea Corona
